Pam, a recognized industry leader, joins Valerio Therapeutics with over 20 years of experience in safety profile characterization and risk management preceded by 10 years of clinical practice in internal medicine. Most recently, as Vice President of Pharmacovigilance and Risk Management at Epizyme, Pam provided PV leadership through two NDA approvals and successfully implemented the post-marketing enterprise. Her experience spans both pharma and biotech, including senior positions at Pfizer, Merck KgA, AVEO, TESARO, Immunogen, and others in the areas of oncology, neurology, and endocrinology. Proven successes, through which she led PV thru development, market authorization, and market surveillance include, TAZVERIK®, Varubi®, Zejula®, Erbitux®, and Rebif®. Pam has a Master in Public Health (MHS) and a Master in Medicine, Physician Assistant (PA) from Duke University School of Medicine, a Masters in Clinical Pathology (MT), a BS in Microbiology, and executive MBA coursework.